What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?

Ian N Olver and Ian E Haines
Med J Aust 2009; 190 (8): . || doi: 10.5694/j.1326-5377.2009.tb02509.x
Published online: 20 April 2009

In reply: We support Gandhi’s contention about the value that can be added to clinical trials by performing correlative laboratory studies. The investigation of biomarkers as potential surrogate endpoints that may indicate efficacy, or lack thereof, earlier than the prolonged time sometimes required to reach a survival endpoint, is one such example. Such studies are often not funded by industry and the importance of funding these, which yield greater clinical benefit, should be recognised by government and non-government agencies.

  • Ian N Olver1
  • Ian E Haines2

  • 1 Cancer Council Australia, Sydney, NSW.
  • 2 Monash University at Cabrini Health, Melbourne, VIC.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.